Cullinan Oncology (CGEM) Stock Forecast & Price Target

Cullinan Therapeutics is attractive because REZILIENT3 showed zipalertinib plus platinum chemotherapy delivered a 65% ORR, 14.5-month mPFS versus 8.5 months for chemo alone, and a 0.50 progression-risk reduction, supporting a credible path to a potential FDA filing completion by YE26. The company also has meaningful near-term optionality from a February 27, 2027 PDUFA date in post-platinum EGFR Ex20Ins+ NSCLC, plus a $100M milestone for 1L approval and up to $130M in cumulative milestones from Taiho, which materially de-risks the commercial upside. Beyond oncology, CLN-978 and CLN-049 add a differentiated autoimmune and AML pipeline, with encouraging early remission data and several expected 2026 updates that broaden the fundamental value proposition.

Cullinan Therapeutics is challenged by a highly uncertain, pipeline-dependent valuation, with the DCF assigning only a 20% probability of launch to CLN-978 and relying on a 95% probability of launch for zipalertinib to justify the model. The negative outlook is reinforced by meaningful execution and regulatory risk, including negative efficacy data, inability to obtain FDA approval, delays advancing candidates, superior competitor data, and medium- to long-term dilution risk as shares rise to 64.5M by end-2026 or 61.7M in the alternative case. Even with signs of pharmacodynamic activity for CLN-978, the company still faces a weak competitive and clinical backdrop in NSCLC and AML, where approval, differentiation, and timely clinical advancement remain uncertain.